ADC Therapeutics SA
ADCT
$1.16
-$0.075-6.10%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -8.42% | 6.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.42% | 6.05% | |||
| Cost of Revenue | 5,880.18% | -92.78% | |||
| Gross Profit | -660.97% | 305.16% | |||
| SG&A Expenses | 0.96% | -1.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.67% | 16.31% | |||
| Operating Income | 8.80% | -22.46% | |||
| Income Before Tax | 29.24% | -20.85% | |||
| Income Tax Expenses | -456.67% | -61.54% | |||
| Earnings from Continuing Operations | 30.12% | -20.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.12% | -20.32% | |||
| EBIT | 8.80% | -22.46% | |||
| EBITDA | 8.89% | -22.68% | |||
| EPS Basic | 30.51% | -9.85% | |||
| Normalized Basic EPS | 29.63% | -10.29% | |||
| EPS Diluted | 30.51% | -9.85% | |||
| Normalized Diluted EPS | 29.63% | -10.29% | |||
| Average Basic Shares Outstanding | 0.55% | 9.54% | |||
| Average Diluted Shares Outstanding | 0.55% | 9.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
